New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

By | June 11, 2021
A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.